Payment overview · 2025
General Payments
$476.49
25 reported records · 9 companies
Healthcare provider profile · identity verified
John O Pittman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROME, GA · NPI 1356313951
Verified facts
What the public records show
CMS Open Payments records show John O Pittman, MD received $476.49 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.85 | 33.3% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $100.23 | 21.0% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.34 | 11.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.89 | 9.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.62 | 5.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.97 | 5.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.61 | 5.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.17 | 4.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.81 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $476.49 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $124.93 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.47 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.34 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.89 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.89 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.76 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.76 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.92 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.92 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.97 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.97 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
140 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 670 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 646 | 193 |
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 113 |
| Alprazolam | Alprazolam | 397 | 57 |
| Lisinopril | Lisinopril | 389 | 104 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 304 | 54 |
| Omeprazole | Omeprazole | 293 | 80 |
| Gabapentin | Gabapentin | 289 | 86 |
| Furosemide | Furosemide | 287 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 282 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 240 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 236 | 71 |
| Metformin Hcl | Metformin Hcl | 228 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 227 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 214 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 48 |
| Clonazepam | Clonazepam | 176 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 167 | 27 |
| Carvedilol | Carvedilol | 157 | 46 |
| Simvastatin | Simvastatin | 153 | 36 |
| Tramadol Hcl | Tramadol Hcl | 148 | 39 |
| Trazodone Hcl | Trazodone Hcl | 147 | 48 |
| Glimepiride | Glimepiride | 146 | 40 |
| Alendronate Sodium | Alendronate Sodium | 142 | 40 |
| Eliquis | Apixaban | 140 | 32 |
| Losartan Potassium | Losartan Potassium | 135 | 44 |
| Enalapril Maleate | Enalapril Maleate | 129 | 37 |
| Montelukast Sodium | Montelukast Sodium | 125 | 37 |
| Potassium Chloride | Potassium Chloride | 121 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 23 |
| Lorazepam | Lorazepam | 111 | 25 |
| Jardiance | Empagliflozin | 105 | 25 |
| Meloxicam | Meloxicam | 104 | 33 |
| Allopurinol | Allopurinol | 99 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 29 |
| Sertraline Hcl | Sertraline Hcl | 99 | 30 |
| Bupropion Hcl | Bupropion Hcl | 97 | 29 |
| Prednisone | Prednisone | 94 | 69 |
| Telmisartan | Telmisartan | 92 | 26 |
| Ezetimibe | Ezetimibe | 91 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 33 |
| Pregabalin | Pregabalin | 84 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 25 |
| Clonidine Hcl | Clonidine Hcl | 81 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 21 |
| Donepezil Hcl | Donepezil Hcl | 67 | 21 |
| Mirtazapine | Mirtazapine | 67 | 21 |
| Cephalexin | Cephalexin | 63 | 55 |
| Celecoxib | Celecoxib | 61 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 16 |
| Atenolol | Atenolol | 56 | 16 |
| Famotidine | Famotidine | 56 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 16 |
| Fenofibrate | Fenofibrate | 55 | 15 |
| Xarelto | Rivaroxaban | 52 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 17 |
| Synthroid | Levothyroxine Sodium | 50 | 11 |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 49 | 13 |
| Lansoprazole | Lansoprazole | 48 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 12 |
| Benazepril Hcl | Benazepril Hcl | 41 | 11 |
| Diazepam | Diazepam | 41 | 16 |
| Diltiazem Hcl | Diltiazem Hcl | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 12 |
| Valsartan | Valsartan | 39 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 18 |
| Promethazine Hcl | Promethazine Hcl | 35 | 21 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 15 |
| Spironolactone | Spironolactone | 34 | 15 |
| Nifedipine Er | Nifedipine | 32 | 12 |
| Ondansetron Odt | Ondansetron | 32 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 18 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 21 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Dexamethasone | Dexamethasone | 21 | 19 |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 13 |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $476.49 · 25 records | ABBVIE INC. | AREXVY, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error